Patients
As of the data cutoff date of 19 April 2021 (enrollment start date, 3 December 2019), a total of 91 patients across three different cohorts from both the dose-escalation and dose-expansion phases of the CHRYSALIS study have received the amivantamab and lazertinib regimen (Fig. 